Reported Earnings • Aug 09
Second quarter 2026 earnings released: EPS: US$0.044 (vs US$0.38 loss in 2Q 2025) Second quarter 2026 results: EPS: US$0.044 (up from US$0.38 loss in 2Q 2025). Revenue: US$2.07m (down 73% from 2Q 2025). Net income: US$17.7m (up US$18.9m from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 149% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings. Announcement • Aug 08
Eightco Holdings Inc Receives Non Compliance Notice from Nasdaq On August 5, 2026, Eightco Holdings Inc. (the Company) received a written notification letter (the Notification Letter) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that, for the preceding 30 consecutive business days (from June 23, 2026 to August 4, 2026), the closing bid price of the Company's common stock was below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The Notification Letter has no immediate effect on the listing or trading of the Company's common stock, which will continue to trade on The Nasdaq Capital Market under the symbol ORBS. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until February 1, 2027, to regain compliance. To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of ten consecutive business days during the compliance period. If the Company chooses to implement a reverse stock split, it must complete the split no later than ten business days prior to the expiration of the compliance period. If the Company does not regain compliance by February 1, 2027, it may be eligible for an additional 180-calendar-day compliance period, provided it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market (other than the bid price requirement) and provides written notice of its intention to cure the deficiency, by effecting a reverse stock split if necessary. If the Company is not eligible or it appears to Nasdaq that the Company will not be able to cure the deficiency, Nasdaq will provide notice that the Company's common stock is subject to delisting, at which time the Company may appeal the determination to a Nasdaq Hearings Panel. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Nasdaq listing requirements. 
